Monte Rosa Therapeutics, Inc. (GLUE): Shareholders' Equity

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2021-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$233.06M

As of 2025-12-31

$487.28M

As of 2026-06-30

-5.0%

3-year compound annual growth

2020-12-31 Shareholders' Equity (USD) 2025-12-31

Period ended	Shareholders' Equity	Change YoY	Source filing
2025-12-31	$233.06M	+4.5%	2026-03-17, Balance as of period end
2024-12-31	$222.94M	+24.4%	2026-03-17, Balance as of period end
2023-12-31	$179.25M	-34.0%	2025-03-20, Balance as of period end
2022-12-31	$271.41M	-21.9%	2024-03-14, Balance as of period end
2021-12-31	$347.51M	n/c	2023-03-16, Balance as of period end
2020-12-31	$48.73M	n/a	2022-03-29, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Shareholders' Equity	Change YoY
Monte Rosa Therapeutics, Inc. (GLUE)	2025-12-31	$233.06M	+4.5%
Atara Biotherapeutics, Inc. (ATRA)	2025-12-31	-$38.50M	n/m
Agenus Inc (AGEN)	2025-12-31	-$271.11M	n/m
ImmunityBio, Inc. (IBRX)	2025-12-31	-$500.47M	n/m
Beam Therapeutics Inc. (BEAM)	2025-12-31	$1.24B	+68.8%
Century Therapeutics, Inc. (IPSC)	2025-12-31	$158.94M	-1.5%
Sutro Biopharma, Inc. (STRO)	2025-12-31	-$132.45M	n/m
Ginkgo Bioworks Holdings, Inc. (DNA)	2025-12-31	$508.59M	-29.0%
REGENXBIO Inc. (RGNX)	2025-12-31	$102.73M	-60.4%

Compare GLUE, ATRA, AGEN, IBRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗